<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590096</url>
  </required_header>
  <id_info>
    <org_study_id>CCHMC# 88-12-2</org_study_id>
    <nct_id>NCT00590096</nct_id>
  </id_info>
  <brief_title>I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma</brief_title>
  <official_title>I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural
      crest tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong
      suspicion of neuroblastoma or pheochromocytoma.

      Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of
      I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration
      of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free
      I-123-iodide
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1991</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <enrollment type="Actual">1380</enrollment>
  <condition>Neuroblastoma</condition>
  <condition>Pheochromocytoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically proven neuroblastoma or pheochromocytoma or strong suspicion
        of neuroblastoma or pheochromocytoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of
             neuroblastoma or pheochromocytoma

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Gelfand, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Chan EL, Harris RE, Emery KH, Gelfand MJ, Collins MH, Gruppo RA. Favorable histology, MYCN-amplified 4S neonatal neuroblastoma. Pediatr Blood Cancer. 2007 Apr;48(4):479-82. Review.</citation>
    <PMID>16333837</PMID>
  </reference>
  <reference>
    <citation>Gelfand MJ. 123I-MIBG uptake in the neck and shoulders of a neuroblastoma patient: damage to sympathetic innervation blocks uptake in brown adipose tissue. Pediatr Radiol. 2004 Jul;34(7):577-9. Epub 2004 Mar 3.</citation>
    <PMID>15205842</PMID>
  </reference>
  <reference>
    <citation>Gelfand MJ. Meta-iodobenzylguanidine in children. Semin Nucl Med. 1993 Jul;23(3):231-42. Review.</citation>
    <PMID>8378796</PMID>
  </reference>
  <results_reference>
    <citation>Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med. 1994 Nov;35(11):1753-7.</citation>
    <PMID>7965151</PMID>
  </results_reference>
  <results_reference>
    <citation>Paltiel HJ, Gelfand MJ, Elgazzar AH, Washburn LC, Harris RE, Masters PR, Golsch GJ. Neural crest tumors: I-123 MIBG imaging in children. Radiology. 1994 Jan;190(1):117-21.</citation>
    <PMID>8259387</PMID>
  </results_reference>
  <results_reference>
    <citation>Englaro EE, Gelfand MJ, Harris RE, Smith HS. I-131 MIBG imaging after bone marrow transplantation for neuroblastoma. Radiology. 1992 Feb;182(2):515-20.</citation>
    <PMID>1732972</PMID>
  </results_reference>
  <results_reference>
    <citation>Elgazzar AH, Gelfand MJ, Washburn LC, Clark J, Nagaraj N, Cummings D, Hughes J, Maxon HR 3rd. I-123 MIBG scintigraphy in adults. A report of clinical experience. Clin Nucl Med. 1995 Feb;20(2):147-52.</citation>
    <PMID>7720307</PMID>
  </results_reference>
  <verification_date>January 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>August 24, 2009</last_update_submitted>
  <last_update_submitted_qc>August 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael J. Gelfand M.D.</name_title>
    <organization>Cincinnati Children's Hospital</organization>
  </responsible_party>
  <keyword>Neuroblastoma</keyword>
  <keyword>Pheochromocytoma</keyword>
  <keyword>MIBG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

